ImmunoForge will be responsible for all pre-clinical and clinical development as well as for manufacturing and commercialisation of the resulting products.
Elasmogen’s NDure albumin binder is based on the company’s soloMER platform. At just 11 kDa, soloMERs are the smallest naturally occurring binding domains. Their simple molecular architecture facilitates easy combination with a wide range of proteins and peptides to enable rapid development of multi-functional therapeutics.
Caroline Barelle, CEO of
“Using Elasmogen’s proprietary technology, ImmunoForge will develop first-in-class dual hybrid agonists,” said Sung-Min Ahn, CEO of ImmunoForge. “The new dual hybrid agonists will strengthen our sarcopenia pipeline and make new breakthroughs in the treatment of neurodegenerative diseases.”